Ian Chau, MD, FRCP of Royal Marsden Hospital discusses the results of a Phase I Study of Ramucirumab + Pembrolizumab (Keytruda)
in patients with advanced
gastric or gastroesophageal
junction
Advertisement Single Below Content
Advertisement Single Below Content
Advertisement Single Below Content